For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Vyndamax and Attruby represents a significant advancement . These novel therapies protect the transthyretin protein, halting its damaging build-up and lessening the impact of the illness. People are now reporting benefits in their quality